Free Trial
NASDAQ:TNFA

TNF Pharmaceuticals 5/15/2024 Earnings Report

TNF Pharmaceuticals logo
$0.16 +0.01 (+5.92%)
Closing price 04:00 PM Eastern
Extended Trading
$0.16 +0.00 (+0.06%)
As of 07:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

TNF Pharmaceuticals EPS Results

Actual EPS
-$5.14
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

TNF Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

TNF Pharmaceuticals Announcement Details

Quarter
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

TNF Pharmaceuticals Earnings Headlines

TNF Pharmaceuticals (TNFA) versus Its Peers Head to Head Comparison
Financial Contrast: TNF Pharmaceuticals (TNFA) and Its Peers
Vladimir Lenin was right…
The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold $3 billion of Amazon… it’s why Nvidia’s CEO just sold $713 million... and it’s why Zuckerberg just sold $1.3 billion in Meta stock. The financial establishment doesn’t want you to know about this… but a controversial new documentary just pulled back the curtain and exposed what’s really going on. It’s called The Final Frontier.
Contrasting TNF Pharmaceuticals (TNFA) & Its Peers
See More TNF Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like TNF Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on TNF Pharmaceuticals and other key companies, straight to your email.

About TNF Pharmaceuticals

TNF Pharmaceuticals (NASDAQ:TNFA) operates as a clinical stage pharmaceutical company. It focuses on developing two novel therapeutic platforms that treat the causes of disease rather than addressing the symptoms. Its MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. The MYMD-1 is being developed to delay aging, increase longevity, and treat autoimmune diseases. The company's second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction, and epilepsy. The Supera-CBD is a novel synthetic derivative of cannabidiol (CBD) and is being developed to address and improve the growing CBD market, which includes FDA approved drugs and CBD products not regulated as drugs. TNF Pharmaceuticals, Inc. was formerly known as MyMD Pharmaceuticals, Inc. and changed its name to TNF Pharmaceuticals, Inc. in July 2024. The company was founded in 2014 and is headquartered in Baltimore, Maryland.

View TNF Pharmaceuticals Profile

More Earnings Resources from MarketBeat